Skip to main content
. 2023 Jun 15;13(6):991. doi: 10.3390/biom13060991

Figure 2.

Figure 2

Survival analysis of 52 patients with ALK−rearranged NSCLC. (A) Maximum percentage reduction from the baseline sum of lesion diameters in 52 patients receiving ALK−TKI treatment. (B) Clinical response in patients receiving ALK−TKI treatments. (C,D) PFS (C) and OS (D) in patients with ALK−rearranged NSCLC stratified by PD-L1 TPS 50%.